3Jia WW, Bu X, Philips D, et al. Rh2, a compound extracted from ginseng, hypersensifizes multidrug-resistant tumor cells to chemotherapy[J]. Can J Physiol Pharmacol, 2004,82(7) :437.
4Nakata H, Kikuehi Y, Tode T, et al. Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells[ J]. Jpn J Cancer Res, 1998,89(7) :733-740.
5Dapas B, Farra R, Grassi M, et al. Role of E2F1-Cyclin El-cyclin E2 circuit in human coronary smooth muscle cell proliferation and therapeutic potential of its downregulation by siRNAs[J]. Mol Med, 2009,15(9-10) :297-306.
6Yasui W, Oue N, Aung PP, et al. Molecular-pathological prognostic factors of gastric cancer: a review [ J ]. Gastric Cancer, 2005,8 (2) :86-94.
7Spruck C, Sun D, Fiegl H, et al. Detection of low molecular weight derivatives of cyelin E1 is a function of cyclin E1 protein levels in breast cancer [ J ]. Cancer Res, 2006,66 ( 14 ) :7355-7360.
8Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy[ J]. Cancer Biol Ther, 2003,2(4 Suppl 1 ) :38-47.
9DonzeUi M, Draetta GF. Regulating mammalian checkpoints through Cde25 inactivation [J]. EMBO Rep, 2003, 4 (7) : 671-677.
10Lehmann GM, MeCabe MJ Jr. Arsenite slows S phase progression via inhibition of CDC25A dual specificity phosphatase gene tran- scription[ J]. Toxieol Sei, 2007,99( 1 ) :70-78.
